Combining CDK4/6 and CDK2 inhibitors with the CXCR1/2 antagonist, SX-682, halted B16F10 tumor growth by blocking tumor cell proliferation and increasing the anti-tumor immune response in the tumor microenvironment. This evidence concerns the gene CXCR1 and neoplasm.